Baxter International Inc. (BAX) on Wednesday said China's State Food and Drug Administration or SFDA has approved ADVATE (Recombinant Human Coagulation Factor VIII for injection) for the control and prophylaxis of bleeding in individuals with hemophilia A.
Over 50,000 people in China are estimated to be living with hemophilia A. ADVATE is infused directly into the bloodstream. It works by temporarily raising the level of factor VIII in the bloodstream, allowing the body's blood clotting process to properly function. ADVATE is now approved in 54 countries worldwide.
''The approval of ADVATE in China marks an important milestone for Baxter and supports our ongoing commitment to treating individuals living with hemophilia,'' said Ludwig Hantson, Ph.D., president of Baxter's BioScience business.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.